Genoa Pharmaceuticals

About Genoa Pharmaceuticals

Genoa Pharmaceuticals, Inc. operates as a biopharmaceutical company with a sharp focus on developing enhanced therapies for severe pulmonary diseases, particularly idiopathic pulmonary fibrosis (IPF). Founded in 2011 by Dr. Mark Surber, an expert in aerosol development, the company was established to advance treatments for this fatal lung condition. Dr. Surber, who also serves as the Chief Scientific Officer, has a personal connection to the disease, as his father and grandfather both succumbed to it. His extensive background includes roles at Mpex Pharmaceuticals and Aires Pharmaceuticals, where he was an inventor on patents for inhaled medicines.

The company's business model is centered on the clinical development and subsequent commercialization of its therapeutic candidates. A significant milestone was achieved in May 2017 when Genoa secured $62 million in a Series A financing round. This funding was pivotal for advancing its lead program, Aerodone™, through Phase 2 clinical trials. The financing was co-led by prominent investors including F-Prime Capital Partners and Edmond de Rothschild Investment Partners. Following this, A. Bruce Montgomery, M.D., was appointed CEO, bringing a wealth of experience in developing and marketing inhaled drugs, including major roles at Gilead, Roche, and Novartis.

Genoa's primary product candidate is Aerodone™, an inhaled formulation of pirfenidone. Pirfenidone is the active ingredient in an existing oral medication for IPF, but the oral version requires large doses to be effective in the lungs, leading to significant side effects due to high drug levels in the bloodstream. Aerodone™ is designed for nebulization and direct aerosol delivery to the lungs. This approach aims to deliver higher concentrations of the drug directly to the site of the disease, which could enhance efficacy while minimizing the systemic side effects associated with the oral treatment. The U.S. FDA granted Aerodone™ orphan drug designation for the treatment of IPF, a key regulatory milestone.